HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Adrenoleukodystrophy — Clinical Guidelines

Overview

Adrenoleukodystrophy (ALD) is an X-linked peroxisomal disorder characterized by impaired degradation of very long chain fatty acids (VLCFA), leading to neurologic and adrenal dysfunction with significant phenotypic variability 1 2 12.

Diagnosis

Biochemical Testing: Elevated VLCFA levels in plasma or fibroblasts confirm the diagnosis 1 11.

Imaging: MRI often reveals characteristic white matter lesions, even in asymptomatic patients 10 6.

Neurological Examination: Assesses for progressive neurologic deficits such as spastic paraparesis, cognitive decline, and extrapyramidal symptoms 3 4 5.

Adrenal Function Tests: Evaluate for adrenal insufficiency through cortisol response to ACTH stimulation 1 9.

CT Scanning: Low-density abnormalities in parieto-occipital lobes with contrast enhancement can support diagnosis 15.

Management

Hematopoietic Stem Cell Transplantation (HSCT): Recommended for early symptomatic boys and asymptomatic boys with MRI abnormalities to halt disease progression 2.

Hormone Replacement Therapy: Lifelong glucocorticoid replacement for adrenal insufficiency 1.

Symptomatic Treatment: Management of complications such as bladder dysfunction with urodynamic studies and potential catheterization 4.

Supportive Care: Includes physical therapy, occupational therapy, and multidisciplinary support for neurologic and cognitive symptoms 3 4.

Special Populations

Pediatrics: Early identification through newborn screening is crucial for timely intervention 1.

Adult Onset: Recognized cases highlight variability in age of onset and symptom presentation 7.

Comorbidities: Management must address concurrent issues like disseminated intravascular coagulopathy and multiorgan failure in acute presentations 5.

Key Recommendations

Screen for Adrenal Insufficiency in males identified with ALD through newborn screening, initiating monitoring and treatment early 1 (Evidence: Strong).

Consider HSCT in asymptomatic boys with MRI abnormalities and symptomatic boys to prevent neurologic deterioration 2 (Evidence: Moderate).

Implement Lifelong Glucocorticoid Replacement for confirmed adrenal insufficiency to manage hypoadrenalism 1 (Evidence: Strong).

Utilize MRI for Early Detection of cerebral involvement even in asymptomatic patients 10 (Evidence: Moderate).

Monitor for Voiding Dysfunction and manage with appropriate urodynamic studies and interventions in symptomatic patients 4 (Evidence: Weak).

References

1 Regelmann MO, Kamboj MK, Miller BS, Nakamoto JM, Sarafoglou K, Shah S et al.. Adrenoleukodystrophy: Guidance for Adrenal Surveillance in Males Identified by Newborn Screen. The Journal of clinical endocrinology and metabolism 2018. link 2 Hudspeth MP, Raymond GV. Immunopathogenesis of adrenoleukodystrophy: current understanding. Journal of neuroimmunology 2007. link 3 Mishra S, Modi M, Das CP, Prabhakar S. Adrenoleukodystrophy manifesting as spinocerebellar degeneration. Neurology India 2006. link 4 Shinbo H, Kageyama S, Hayami S, Ushiyama T, Suzuki K, Fujita K et al.. Voiding dysfunction in a patient with adolescent adrenoleukodystrophy. International journal of urology : official journal of the Japanese Urological Association 2001. link 5 Ravid S, Diamond AS, Eviatar L. Coma as an acute presentation of adrenoleukodystrophy. Pediatric neurology 2000. link00141-1) 6 Castellote A, Vera J, Vazquez E, Roig M, Belmonte JA, Rovira A. MR in adrenoleukodystrophy: atypical presentation as bilateral frontal demyelination. AJNR. American journal of neuroradiology 1995. link 7 Angus B, de Silva R, Davidson R, Bone I. A family with adult-onset cerebral adrenoleucodystrophy. Journal of neurology 1994. link 8 Sereni C, Paturneau-Jouas M, Aubourg P, Baumann N, Feingold J. Adrenoleukodystrophy in France: an epidemiological study. Neuroepidemiology 1993. link 9 Watkiss E, Webb T, Bundey S. Is skewed X inactivation responsible for symptoms in female carriers for adrenoleucodystrophy?. Journal of medical genetics 1993. link 10 Aubourg P, Sellier N, Chaussain JL, Kalifa G. MRI detects cerebral involvement in neurologically asymptomatic patients with adrenoleukodystrophy. Neurology 1989. link 11 Kelley RI, Datta NS, Dobyns WB, Hajra AK, Moser AB, Noetzel MJ et al.. Neonatal adrenoleukodystrophy: new cases, biochemical studies, and differentiation from Zellweger and related peroxisomal polydystrophy syndromes. American journal of medical genetics 1986. link 12 Powers JM. Adreno-leukodystrophy (adreno-testiculo-leukomyelo-neuropathic-complex). Clinical neuropathology 1985. link 13 Benke PJ, Reyes PF, Parker JC. New form of adrenoleukodystrophy. Human genetics 1981. link 14 Hormia M. Diffuse cerebral sclerosis, melanoderma and adrenal insufficiency (adreno-leukodystrophy). Acta neurologica Scandinavica 1978. link 15 Greenberg HS, Halverson D, Lane B. CT scanning and diagnosis of adrenoleukodystrophy. Neurology 1977. link

Adrenoleukodystrophy